| Literature DB >> 25998561 |
Huizi Sha1, Rutian Li1, Xinyu Bian1, Qin Liu1, Chen Xie2, Xiaoyan Xin3, Weiwei Kong1, Xiaoping Qian1, Xiqun Jiang2, Wenjing Hu4, Baorui Liu5.
Abstract
It has been a major challenge for drug penetration in solid tumor tissues because of the complicated tumor microenvironment. We have previously constructed a protein of bispecific targets and high permeability named anti-EGFR-iRGD and investigated its inhibiting cell proliferation of gastric cancer. Paclitaxel (PTX) is widely used for treating various kinds of cancer. In this paper, we investigated the effects of anti-EGFR-iRGD in combination with chemotherapeutic drugs including PTX in epidermal growth factor receptor highly expressing gastric cancer. We demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time and investigated the mechanism of this synergy effect. Our results provide impetus for further studies to use anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients.Entities:
Keywords: 5-Fluorouracil (PubChem CID: 3385); Anti-EGFR single-domain antibody; Fluorescein isothiocyanate (PubChem CID: 18730); Gastric cancer; Irinotecan (PubChem CID: 60838); Multicellular spheroids; Paclitaxel; Paclitaxel (PubChem CID: 36314); Recombinant protein; iRGD
Mesh：
Substances：
Year: 2015 PMID： 25998561 DOI： 10.1016/j.ejps.2015.05.020
Source DB: PubMed Journal: Eur J Pharm Sci ISSN： 0928-0987 Impact factor: 4.384